Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
PGEN - Precigen, Inc.
Market Cap 306.58M P/E - EPS this Y 12.80% Ern Qtrly Grth -
Income -95.9M Forward P/E -2.79 EPS next Y 20.60% 50D Avg Chg -2.00%
Sales 6.22M PEG -1.72 EPS past 5Y - 200D Avg Chg -14.00%
Dividend N/A Price/Book 1.66 EPS next 5Y 2.40% 52W High Chg -59.00%
Recommedations 2.20 Quick Ratio 2.80 Shares Outstanding 252.42M 52W Low Chg 48.00%
Insider Own 11.44% ROA -30.29% Shares Float 122.48M Beta 1.77
Inst Own 63.90% ROE -78.37% Shares Shorted/Prior 15.96M/16.91M Price 1.20
Gross Margin - Profit Margin - Avg. Volume 1,214,056 Target Price 9.00
Oper. Margin -1,904.64% Earnings Date May 8 Volume 1,042,734 Change -6.98%
Healthcare | Biotechnology | United States
About Precigen, Inc.

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Precigen, Inc. News
04/24/24 Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
04/24/24 Actym Therapeutics Appoints Thomas Smart as CEO
03/28/24 Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
03/20/24 Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call Transcript
03/19/24 Precigen Inc (PGEN) Reports Full Year 2023 Financial Results
03/19/24 Precigen Reports Full Year 2023 Financial Results and Business Updates
03/12/24 Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
04:05 PM Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
02/20/24 Precigen, Inc. (NASDAQ:PGEN): When Will It Breakeven?
02/06/24 Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
02/04/24 Insider Stock Buying Reaches US$1.72m On Precigen
01/16/24 Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
01/08/24 Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference
12/27/23 Even after rising 15% this past week, Precigen (NASDAQ:PGEN) shareholders are still down 86% over the past three years
12/18/23 Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference
11/29/23 Precigen to Participate in the JMP Securities Hematology and Oncology Summit
11/09/23 Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs
11/07/23 Precigen to Participate in the Stifel 2023 Healthcare Conference
09/25/23 While institutions own 26% of Precigen, Inc. (NASDAQ:PGEN), private equity firms are its largest shareholders with 37% ownership
09/19/23 Precigen to Participate in Upcoming Leading Investor and Industry Conferences
PGEN Chatroom

User Image Sarf15 Posted - 2 hours ago

$PGEN https://apple.news/AgGMAccY9T3GTuKm6I4e82g

User Image Enjoyycall Posted - 2 days ago

$PGEN tick tock

User Image rubraquercus Posted - 2 days ago

$PGEN no wonder they can't sell exemplar..no one wants that pig shit MAR | 21 | 2024 World’s First Genetically-Edited Pig Kidney Transplant into Living Recipient Performed at Massachusetts General Hospital Brandon [email protected] The pig kidney was provided by eGenesis of Cambridge, Mass., from a pig donor that was genetically-edited 69 times using CRISPR-Cas9 technology to remove harmful pig genes and add certain human genes to improve its compatibility with humans. Additionally, scientists inactivated porcine endogenous retroviruses in the pig donor to eliminate any risk of infection in humans. Over the past five years, MGH and eGenesis have conducted extensive collaborative research, with the findings published in Nature in 2023.

User Image DavidHasselhoff Posted - 4 days ago

$PGEN after I don’t even know how many years in this stock I’m out. Best of luck!

User Image DavidHasselhoff Posted - 04/30/24

$PGEN I think my time in this thing is about done. Horrible stock

User Image Bigda21 Posted - 04/28/24

@chrisfromyahoo where do you think the next round of financing comes from for $PGEN?

User Image chrisfromyahoo Posted - 04/26/24

$PGEN I have a full position! Good luck to the longs. Trust the science, stay strong, and hold for the long term. Have a good summer everyone! I’ll be on X praising Precigen! Be well and prosper Chris Suplick

User Image chrisfromyahoo Posted - 04/26/24

$PGEN Good morning all! Let’s have a great Friday and an even better weekend. Go Precigen!!!

User Image Enjoyycall Posted - 04/25/24

$PGEN

User Image chrisfromyahoo Posted - 04/25/24

$PGEN I’ve been following RJ Kirk for yrs and i’m proud to say I have man crush on him. from country lawyer to billionaire. nice work! Helen is a rock star who is truly devoted to her craft. Good luck to the Precigen longs!

User Image chrisfromyahoo Posted - 04/25/24

$PGEN How is everyone feeling? I feel great! EXCITED! as my favorite CEO Helen Sabzevari would like to say.

User Image chrisfromyahoo Posted - 04/25/24

$PGEN i posted my holdings on X good luck to longs!🤘

User Image chrisfromyahoo Posted - 04/25/24

$PGEN i bought 10k more at 12:15pm today. anyone see that? 😂

User Image chrisfromyahoo Posted - 04/25/24

$PGEN come on! another drop for ants. i need this back below $1.30

User Image DavidHasselhoff Posted - 04/25/24

$PGEN all I want is this thing to go to $2.10.

User Image rubraquercus Posted - 04/25/24

$PGEN the street sure is impressed....uhm, not..... 04/24/2024 - 10:20 AM The pigeon, a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data from the pivotal Phase 2 study of PRGN-2012 AdenoVerse immunotherapy for the treatment of patients with recurrent respiratory papillomatosis (RRP) will be presented in a late-breaking oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 31 to June 4, 2024 at McCormick Place in Chicago, Illinois.

User Image chrisfromyahoo Posted - 04/25/24

$PGEN I’m hoping for a huge drop today! not much time to pick up cheap shares before launch.

User Image chrisfromyahoo Posted - 04/24/24

$PGEN Boom! Precigen short interest continues to fall

User Image chrisfromyahoo Posted - 04/24/24

$PGEN Short Sale report should be out after the bell. Im hoping they added 😂

User Image chrisfromyahoo Posted - 04/24/24

$PGEN per the PGEN yahoo group, Precigen is also showing posters of PGEN-2009 at ASCO; paired w Keytruda. Lets go!!

User Image 11thestate Posted - 04/24/24

$PGEN

User Image Stock_Titan Posted - 04/24/24

$PGEN Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting https://www.stocktitan.net/news/PGEN/precigen-to-present-late-breaking-abstract-for-pivotal-phase-2-study-0ngjwgb9so82.html

User Image DavidHasselhoff Posted - 04/23/24

$PGEN I guess it’s good that it keeps going up. 🤷🏼‍♂️

User Image DavidHasselhoff Posted - 04/22/24

$PGEN

User Image forgottenchuck Posted - 04/17/24

$PGEN wow 9 billion

User Image rubraquercus Posted - 04/17/24

$PGEN how many times over as many months has this lying bitch told us a partnership was coming?

User Image Enjoyycall Posted - 04/15/24

$PGEN 👀

User Image DavidHasselhoff Posted - 04/12/24

$PGEN

User Image Wacousta Posted - 04/11/24

$PGEN “Let your plans be dark and impenetrable as night, and when you move, fall like a thunderbolt”. Sun Tzu | The Art of War The unknowns mount.

User Image Enjoyycall Posted - 04/10/24

$PGEN Uptick in volume today, price held up nicely. 👀

Analyst Ratings
JP Morgan Underweight Mar 22, 24
JMP Securities Market Outperform Mar 20, 24
HC Wainwright & Co. Buy Mar 20, 24
HC Wainwright & Co. Buy Aug 10, 23
JMP Securities Market Outperform Jun 5, 23
JP Morgan Neutral May 23, 23
JMP Securities Market Outperform May 11, 23
JMP Securities Market Outperform Mar 7, 23
HC Wainwright & Co. Buy Mar 7, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
KIRK RANDAL J Director Director Dec 28 Buy 1.41 96,686 136,327 1,096,686 12/29/23
KINDLER JEFFREY B Director Director Dec 28 Sell 1.41 96,686 136,327 238,275 12/29/23
Sabzevari Helen President and CEO President and CEO Aug 23 Sell 1.53 76,969 117,763 1,560,004 08/25/23
Lehr Donald P. Chief Legal Officer Chief Legal Officer Aug 23 Sell 1.64 10,947 17,953 428,916 08/25/23
Shah Rutul R Chief Operating Offi.. Chief Operating Officer Aug 23 Sell 1.64 5,388 8,836 133,474 08/25/23
Perez Jeffrey Thomas SVP, IP Affairs SVP, IP Affairs Aug 23 Sell 1.64 8,891 14,581 458,903 08/25/23
Thomasian Harry Jr. Chief Financial Offi.. Chief Financial Officer Aug 23 Sell 1.64 9,045 14,834 161,051 08/25/23
Perez Jeffrey Thomas SVP, IP Affairs SVP, IP Affairs Aug 16 Sell 1.55 8,741 13,549 448,916 08/18/23
Thomasian Harry Jr. Chief Financial Offi.. Chief Financial Officer Aug 16 Sell 1.55 8,893 13,784 152,162 08/18/23
Lehr Donald P. Chief Legal Officer Chief Legal Officer Aug 16 Sell 1.55 10,762 16,681 418,153 08/18/23
Shah Rutul R Chief Operating Offi.. Chief Operating Officer Aug 16 Sell 1.55 5,298 8,212 123,382 08/18/23
Sabzevari Helen President and CEO President and CEO Aug 16 Sell 1.66 55,855 92,719 1,495,386 08/18/23
KIRK RANDAL J Director Director Aug 15 Buy 1.52 500,000 760,000 31,837,786 08/17/23
Shah Rutul R Chief Operating Offi.. Chief Operating Officer Aug 09 Sell 1.21 5,429 6,569 113,200 08/11/23
Lehr Donald P. Chief Legal Officer Chief Legal Officer Aug 09 Sell 1.21 11,026 13,341 407,205 08/11/23
Thomasian Harry Jr. Chief Financial Offi.. Chief Financial Officer Aug 09 Sell 1.21 6,852 8,291 143,121 08/11/23
Perez Jeffrey Thomas SVP, IP Affairs SVP, IP Affairs Aug 09 Sell 1.21 8,956 10,837 438,779 08/11/23
Sabzevari Helen President and CEO President and CEO Aug 09 Sell 1.44 41,436 59,668 1,409,654 08/11/23
Perez Jeffrey Thomas SVP, IP Affairs SVP, IP Affairs Aug 02 Sell 1.2 8,789 10,547 428,857 08/04/23
Lehr Donald P. Chief Legal Officer Chief Legal Officer Aug 02 Sell 1.2 10,821 12,985 396,521 08/04/23
Thomasian Harry Jr. Chief Financial Offi.. Chief Financial Officer Aug 02 Sell 1.2 6,724 8,069 132,039 08/04/23
Shah Rutul R Chief Operating Offi.. Chief Operating Officer Aug 02 Sell 1.2 5,328 6,394 103,149 08/04/23
Sabzevari Helen President and CEO President and CEO Aug 02 Sell 1.1 52,870 58,157 1,309,503 08/04/23
Shah Rutul R Chief Operating Offi.. Chief Operating Officer Jan 27 Buy 1.75 9,142 15,998 62,037 01/30/23
Perez Jeffrey Thomas SVP, IP Affairs SVP, IP Affairs Jan 27 Buy 1.75 28,571 49,999 381,012 01/30/23
Sabzevari Helen President and CEO President and CEO Jan 27 Buy 1.75 22,857 40,000 937,613 01/30/23
Thomasian Harry Jr. Chief Financial Offi.. Chief Financial Officer Jan 27 Buy 1.75 28,571 49,999 84,961 01/30/23
Thomasian Harry Jr. Chief Financial Offi.. Chief Financial Officer Aug 23 Buy 2.09 24,500 51,205 56,390 08/24/22
KINDLER JEFFREY B Director Director Aug 11 Sell 2.30 50,000 115,000 214,411 08/15/22
Perez Jeffrey Thomas SVP, IP Affairs SVP, IP Affairs May 16 Sell 1.28 14,778 18,916 333,502 05/18/22
Thomasian Harry Jr. Chief Financial Offi.. Chief Financial Officer May 16 Sell 1.28 2,719 3,480 31,890 05/18/22
Lehr Donald P. Chief Legal Officer Chief Legal Officer May 16 Sell 1.28 18,196 23,291 323,274 05/18/22
Sabzevari Helen President and CEO President and CEO May 12 Sell 1.19 177,968 211,782 897,091 05/16/22
KIRK RANDAL J Director Director Nov 19 Buy 3.61 1,000,000 3,610,000 1,000,000 11/23/21
Ares Trading S.A. 10% Owner 10% Owner Oct 12 Sell 4.64 143,796 667,213 20,647,152 10/14/21
Ares Trading S.A. 10% Owner 10% Owner Oct 08 Sell 4.68 116,204 543,835 20,790,948 10/12/21
Ares Trading S.A. 10% Owner 10% Owner Oct 06 Sell 4.86 113,100 549,666 20,907,152 10/08/21
Ares Trading S.A. 10% Owner 10% Owner Aug 26 Sell 5.83 78,607 458,279 21,870,152 08/26/21